Mahwah, NJ, United States of America

Paul R Hartig


Average Co-Inventor Count = 3.3

ph-index = 11

Forward Citations = 350(Granted Patents)


Location History:

  • Princeton, NJ (US) (1995 - 2000)
  • Mahwah, NJ (US) (1991 - 2002)
  • Pennington, NJ (US) (1998 - 2003)
  • Kinnelon, NJ (US) (1995 - 2005)

Company Filing History:


Years Active: 1991-2005

Loading Chart...
33 patents (USPTO):Explore Patents

Title: **The Innovative Contributions of Paul R. Hartig**

Introduction

Paul R. Hartig, located in Mahwah, NJ, is a prominent inventor with 33 patented innovations to his name. His work primarily revolves around advancements in biochemistry, specifically focusing on receptors and therapeutic compounds, making significant contributions to medical science.

Latest Patents

Hartig's recent inventions showcase his expertise in the field. One notable patent is titled "DNA encoding a human dopamine D1 receptor and uses thereof." This invention provides isolated nucleic acid molecules encoding the human dopamine D1 receptor, isolated proteins, vectors that comprise these nucleic acids, mammalian cells containing such vectors, and antibodies directed at the receptor. It also includes nucleic acid probes for detecting encoding and antisense oligonucleotides that are complementary to sequences of this nucleic acid. Furthermore, it outlines pharmaceutical compounds related to the human dopamine D1 receptor and explores methods for determining ligand binding, detecting expression, drug screening, and treatment involving this receptor.

Another significant patent is for the "Use of α1C specific compounds to treat benign prostatic hyperplasia." This invention details a method for treating benign prostatic hyperplasia by administering a therapeutically effective compound that binds selectively to human α adrenergic receptors with a substantially greater binding affinity than that with which the compound binds to other related receptors.

Career Highlights

Throughout his career, Paul Hartig has been associated with notable companies, including Synaptic Pharmaceutical Corporation and Neurogenetic Corporation. His innovations have paved the way for advancements in therapeutic strategies for various medical conditions.

Collaborations

Hartig has collaborated with esteemed colleagues in the field, including Theresa A. Branchek and Richard L. Weinshank. These collaborations have undoubtedly enhanced the innovation landscape in biopharmaceutical research.

Conclusion

Paul R. Hartig is an influential figure in the realm of biochemistry, with a strong portfolio of patents that have the potential to impact medical treatment and drug development significantly. His inventive contributions continue to drive progress and innovation in understanding human receptors and developing therapeutic applications.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…